ACR Convergence 2026

November 6–11, 2026
Orlando, US



LupusHub

TOP ABSTRACTS

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2026, November 6–11, 2026, Orlando, US, the Lupus Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lupus.

Intended for healthcare professionals. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

ACR 2026: Top abstracts in lupus

November 6–11, 2026

Oral presentations: Sunday, November 8			
Abstract	**Title**	**Presenter**	**Time (EST)**
0872 View	Litifilimab improves clinician and patient reported skin changes in cutaneous lupus erythematosus: 52-week results from the phase 2 study, AMETHYST Part A	Joseph Merola	08:30–08:45
0875 View	Nipocalimab in SLE: First-in-class efficacy and safety results demonstrating proof of concept for FcRn blockade from a phase 2 study	Richard Furie	09:15–09:30
0921 View	Assessment of renal, hematological, and immunological lab values among patients diagnosed with systemic lupus erythematosus pre- and post-anifrolumab treatment initiation: A large real-world analysis	Demetrios Psihopaidas	13:15–13:30

Oral presentations: Monday, November 9			
Abstract	**Title**	**Presenter**	**Time (EST)**
1823 View	Obinutuzumab induces histologic remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: Exploratory analyses from a phase III trial	Richard Furie	10:45–11:00
1844 View	Adverse pregnancy outcomes in the lupus in prEGnAnCY (LEGACY) cohort: Anti-phosphatidylserine/prothrombin IgG antibodies are stronger predictors than lupus anticoagulant	Reem Farhat	08:00–08:15
1862 View	Post-treatment proteinuria imperfectly predicts histological remission in lupus nephritis: Repeat biopsy data from ReBioLup support reappraisal of trial endpoints	Ioannis Parodis	13:00–13:15
1916 View	Validation of Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) for evaluation of patients with cutaneous lupus erythematosus in clinical trials	Victoria Werth	15:00–15:15

Oral presentations: Tuesday, November 10			
Abstract	**Title**	**Presenter**	**Time (EST)**
2839 View	A new endpoint for SLE clinical trials: The Treatment Response Measure for Systemic Lupus Erythematosus Clinical Trials (TRM-SLE)	Eric Morand	08:00–08:15
2870 View	Toward improved patient-centered outcome assessment in SLE trials: Development of a novel patient reported outcomes set by the Lupus Accelerating Breakthroughs Consortium PRO measures working group	Madison Lewis	13:15–13:30

Oral presentations: Wednesday, November 11			
Abstract	**Title**	**Presenter**	**Time (EST)**
LB23 View	A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of afimetoran, an oral, once-daily equipotent TLR 7/8 inhibitor, in participants with active systemic lupus erythematosus	Kenneth Kalunian	09:00–09:15

Posters			
Abstract	**Title**	**Presenter**	**Date and time (EST)**
0259 View	Cenerimod, a selective S1PR1 modulator, induces changes in BCR and TCR repertoire in systemic lupus erythematosus: Post-hoc analysis from the placebo-controlled phase 2b CARE trial	Mark Murphy	Sunday, November 8, 10:30–12:30
0269 View	Efficacy and safety of edecesertib (GS-5718) for the treatment of cutaneous lupus erythematosus: Results from a Ph2a study	Victoria Werth	Sunday, November 8, 10:30–12:30
0280 View	Safety and efficacy of AZD0120 (GC012F), a dual-targeting CD19/BCMA CAR-T cell therapy, in refractory systemic lupus erythematosus: Phase 1/2 interim results	Qiong Fu	Sunday, November 8, 10:30–12:30
1220 View	Exploratory urinary biomarkers from an open-label phase 1/2 study of rapcabtagene autoleucel (YTB323) suggest reduced intrarenal inflammation in severe refractory systemic lupus erythematosus	Andrea Fava	Monday, November 9, 10:30–12:30
1231 View	Low five year mortality in SLE treated with belimumab: Findings from the prospective, global, SABLE registry	Ronald van Vollenhoven	Monday, November 9, 10:30–12:30
1234 View	Off-the-shelf CD19 CAR T-cell therapy demonstrates feasibility of outpatient administration, expanding access to community-based care	Aikaterini Thanou	Monday, November 9, 10:30–12:30
1240 View	Safety and efficacy of subcutaneous ianalumab (VAY736) post-b cell recovery in patients with systemic lupus erythematosus: End-of-study results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study	Edward Vital	Monday, November 9, 10:30–12:30
1296 View	Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Application to a phase 3 trial of dapirolizumab pegol	Eric Morand	Monday, November 9, 10:30–12:30
2213 View	Long-term multidomain clinical response to deucravacitinib in SLE: Four-year integrated analyses from a phase 2 randomized study and its long-term extension	Ronald van Vollenhoven	Tuesday, November 10, 10:30–12:30
2216 View	Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in adults and adolescents with severe, refractory systemic lupus erythematosus (srSLE): Findings from the phase I CARLYSLE study	Claire Roddie	Tuesday, November 10, 10:30–12:30

2224 **View**	Safety and efficacy of enpatoran in lupus: Results up to 109 weeks of the phase II WILLOW long-term extension study	Eric Morand	Tuesday, November 10, 10:30–12:30
LB04 **View**	Durable responses at ≥ 12 months with zola-cel in severe refractory systemic lupus erythematosus: Safety, efficacy, and translational findings from the full phase 1 Breakfree-1 cohort	Emily Littlejohn	Tuesday, November 10, 10:30–12:30
LB17 **View**	Mesenchymal stromal cells for refractory lupus: Results from the phase II multicenter double-blind, placebo-controlled trial	Gary Gilkeson	Tuesday, November 10, 10:30–12:30

#ACR26

Follow us on X to keep up to date with the latest from the congress

@Lupus_Hub

LupusHub

Brought to you by

SES

Intended for healthcare professionals. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.